Business
Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman
Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman.
About this update from Enzolytics Inc.
[{"type":"text","content":"\n \n \n Eco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman\n \n \nEco-Petroleum Solutions, Inc. Releases Letter from CEO and Chairman\n \n MONROVIA, CA--(Marketwired - Jun 16, 2017) -  Eco Petroleum Solutions, Inc. (OTC PINK: ECPO) published today the first letter to the shareholders from the newly appointed Chief Executive Officer and Chairman of ECPO, Harry Zhabilov.\n Over 50% of the dollars spent on treatment are being spent in the US with an additional 30% being spent in Europe, with 20% of the expenditures for treatment being spent in the rest of the world.\n Over $19 billion is being spent on education and prevention in low and middle income countries.\n It is estimated by the Harvard P H Chan School of Public Health as published in the March 2016 article entitled HIV/AIDS long term costs high - and unaffordable to most affected countries, \"that the price tag for providing long-term HIV/AIDS prevention and treatment in 2015-2050 in the nine sub-Saharan countries most affected by the epidemic ranges from $98 billion at current coverage levels to $261 billion if coverage is scaled up.\"\n Dear Eco-Petroleum Shareholders,\n As the newly appointed CEO and Chairman of Eco-Petroleum Solutions, Inc. it is with great excitement that I address the shareholders of the Company and of Immunotech Laboratories, Inc. regarding our future potential as we transition ECPO into the Immunotherapy Medical Industry.\n IMMB is the exclusive license holder of an innovative US Patented treatment for HIV/AIDS and Hepatitis C which has successfully completed Phase III clinical testing at one of the leading Hospitals in Europe, the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases in Sofia, Bulgaria. A copy of the final report can be viewed at www.Immunotechlab.com and www.immunH.com.  The participants in the Phase III testing were all salvage patients in various advanced stages of the HIV/AIDS virus. \n The final report issued by the Ministry of Health demonstrated improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK and of the index CD4/CD8. The patients demonstrated significant decreases in their viral loads. The treatment had a positive effect on opportunistic infections related to the progress ...